Interferons News and Research

RSS

SARS-CoV-2 protein effectively shuts down production of proteins in the host, study shows

A detailed study of a SARS-Cov-2 protein, Nsp1, with a central role in weakening the host anti-viral immune response shows that it effectively shuts down production ofproteins in the host.

17 Jul 2020

Certain antibodies may cause the dangerous part of COVID-19 disease

A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.

15 Jul 2020

As winter comes other viruses will compete with SARS-CoV-2 for susceptible hosts

A new study published on the preprint server medRxiv in July 2020 traces how COVID-19 became the predominant cause of respiratory infection in the period from early January until the present.

10 Jul 2020

Potential new biomarker could improve COVID-19 diagnosis

Researchers at Montpellier University Hospital have discovered that an interferon-inducible receptor expressed on monocytes could be a useful biomarker for the rapid triaging of patients suspected to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

30 Jun 2020

Dysregulated inflammation in severe COVID-19

The continuing COVID-19 pandemic has so far caused 9.58 million cases and more than 488,000 deaths within just six months. The spectrum of disease is broad, from completely asymptomatic cases to critical illness ending in death. Now, a new paper by researchers from Yale University and published on the preprint server medRxiv* in June 2020 identifies an imbalance in immunological response that is linked to poor outcomes and early biomarkers that may help predict the course of the disease.

25 Jun 2020

ILC Therapeutics announces research partnership with University of St Andrews to fight against COVID-19

UK-based biotechnology firm ILC Therapeutics has announced a research partnership with the University of St Andrews in a bid to progress a therapeutic drug which can treat COVID-19 towards clinical trials.

23 Jun 2020

ACE2 and pattern recognition receptor genes increase with age

A recent study by researchers in California and published on the preprint server bioRxiv* in June 2020 shows that advancing age is associated with increased expression of pattern recognition receptor (PRR) genes and ACE2 receptors, possibly accounting in part for the increased severity of the disease in older adults.

17 Jun 2020

Inhaled steroids reduce ACE2 expression in COPD lungs

A new study by scientists at Imperial College London, University of Newcastle and Prokarium, and published on the preprint server bioRxiv* in June 2020 examines the role played by inhaled corticosteroids (ICS) in the risk of acquisition of COVID-19 infection by COPD patients.

15 Jun 2020

Interferons being tested for COVID-19 may increase susceptibility to bacterial infections

Two separate studies in mice suggest that a class of interferons being evaluated in clinical trials as a therapy for COVID-19 may increase susceptibility to bacterial infections, depending on how long patients are exposed to it, and when they receive it.

12 Jun 2020

Type III interferons can increase risk of bacterial "superinfections" in the lung, research shows

Interferons and other cytokines produced by the immune system are important defenses against viral infections, but as we have seen in COVID-19, they can also contribute to damaging, potentially life-threatening lung inflammation.

12 Jun 2020

Unique antiviral action of cholesterol 25-hydroxylase against SARS-CoV-2

A new study by U.S. and Chinese researchers, currently available on the bioRxiv* preprint server, demonstrates how cholesterol 25-hydroxylase and its enzymatic product 25-hydroxycholesterol can inhibit membrane fus

10 Jun 2020

Zinc-finger antiviral protein makes SARS-CoV-2 highly susceptible to interferons

By looking into zinc-finger antiviral proteins (ZAP), a new study from Germany and the United Kingdom (UK) and available on the preprint server bioRxiv suggests that zoonotic transmission of a coronavirus with a specific genetic make-up facilitated the pandemic spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also its sensitivity to interferons.

7 Jun 2020

Study reveals how a fat cell's immune response worsens obesity

When obesity occurs, a person's own fat cells can set off a complex inflammatory chain reaction that can further disrupt metabolism and weaken immune response--potentially placing people at higher risk of poor outcomes from a variety of diseases and infections, including COVID-19.

2 Jun 2020

Does interferon therapy work in COVID-19?

A new study published on the preprint site medRxiv in May 2020 reports on the efficacy of interferons in treating COVID-19. The research could help evaluate the place of such therapy in the management of this disease.

2 Jun 2020

Study: Glucocorticoids are harmful for patients suffering from viral respiratory infections

Glucocorticoids are widely used in treating acute respiratory distress syndrome (ARDS) despite there being no indisputable scientific evidence of their effectiveness.

29 May 2020

Researchers identify genetic mechanisms that produce radioresistance in cancer cells

Cancer stem cells are a cell type that was previously little known. They are resistant to irradiation and prevent the effective treatment of many types of cancer. A research group from Innsbruck has now identified two genetic mechanisms that produce this radioresistance.

26 May 2020

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).

22 May 2020

Antiviral drug can help accelerate recovery of COVID-19 patients, study shows

An international team of researchers led by Dr. Eleanor Fish, emerita scientist at the Toronto General Hospital Research Institute, University Health Network, and professor in the University of Toronto's Department of Immunology, has shown for the first time that an antiviral drug can help speed up the recovery of COVID-19 patients.

15 May 2020

Researchers investigate the troubling trend of heart injury in COVID-19 patients

Researchers are finding about half of all patients with COVID-19 admitted to an intensive care unit have heart damage.